Study On The Effect Of Recombinant Human Thrombopoietin After Autologous Stem Cell Transplantation

Objective:We analyzed the clinical data of autologous transplant patients and studied the hematopoietic reconstruction and prognosis of the disease difference in the prognosis of autologous transplant patients treated with recombinant human thrombopoietin.The purpose of this study was to investigate the effect of recombinant human thrombopoietin in autologous transplantation,analyze the appropriate population and provide theoretical basis for this.Methods:We collected the clinical index of 59 patients who received autologous transplantation in our hospital from January 2012 to January 2018.It was retrospectively analyzed,with a follow-up of at least 12 months.The patients were divided into two groups:treatment group(n=30)and the untreatment group(n=29).SPSS 23.0 was used for analysis,Chi-square test was used for count data.The OS rates were calculated by Kaplan-Meier curves,long-rank and Breslow test methods were used for comparison of survival rates between groups.P values less than 0.05 were considered to indicate statistical significance.Results:The 59 patients enrolled in the study,treatment group and untreatment group:the median time to platelet engraftment of 10 days and 10 days(p=0.562),the median time to granulocyte engraftment of 11 days and 10 days(p=0.172),the median time to platelet recovery to 50×10~9/L of 15.5 days and 15 days(p=0.819),the median time to platelet recovery to 100×10~9/L of 52 days and 50 days(p=0.404),the median amount of platelet transfusion 2.5 treatments and 3 treatments(p=0.044),TRM(6.60%vs.6.80%,p=0.972),1-year OS(96.70%vs.90%,p=0.276),1-year PFS(72.70%vs.82.80%,p=0.447),3-year OS(83.40%vs.81%,p=0.798),3-year PFS(51.90%vs.74.90%,p=0.214),5-year OS(83.40%vs.81%,p=0.798),5-year PFS(51.90%vs.59.90%,p=0.228)Diagnosis of patients after stratification had statistical difference.The median amount of platelet transfusion of autologous transplant patient with lymphomatreated group is 2 treatment untreated group is the 4 treatments(p=0.008)Conclusions:1.The application of recombinant human thrombopoietin in patients with autologous transplantation showed no impact on hematopoietic reconstruction,platelet recovery time or decreased platelet transfusion2.The application of recombinant human thrombopoietin in patients with autologous transplantation showed no adverse events,no impact on survival or progression-free survival time3.Autologous transplant patients with lymphoma use recombinant human thrombopoietin require less platelet transfusion...